Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature.

Yoo et al. (2007) scanned every paper on donepezil and learning in special groups. They looked at autism, Down syndrome, brain injury, ADHD, and dementia.

The team pulled both animal and human studies. They wanted to see if the drug boosts memory or thinking in people with developmental disabilities.

Rats and mice learned mazes faster on donepezil. Human data were thin and most lacked behavior measures.

No solid ABA studies existed. The authors say we still do not know if the pill truly helps clients in clinic seats.

The same gap shows up in dementia work. Aggio et al. (2018) found only 16 behavior-analytic cognition studies, and Lucock et al. (2019) found only six for adults with both IDD and dementia.

Autism tells a different story. Reichow (2012) and Howlin et al. (2009) show EIBI raises IQ, while Van Gaasbeek et al. (2026) prove community ABA still works. These papers supply the rigorous behavior data Helen’s review says is missing.

So the field has moved on for autism but remains nearly empty for dementia and other developmental groups.

If you serve adults with Down syndrome or dementia, donepezil is still a question mark. Push for baseline and repeated behavior probes before and after any med change. Partner with physicians to run single-case tests. Your data could fill the hole Helen flagged and finally tell us if the pill is worth the bill.